Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Pharmacists' confidence diminishes due to mounting financial pressure, Lloyds Bank’s survey reveals

Growing financial pressures has dented pharmacists confidence, despite an anticipated increase in profits in the current year, latest Lloyds Bank Healthcare Confidence Index revealed on Tuesday (November 9).

Though short-term confidence among pharmacists increased for the fifth consecutive year, ticking up from 27 to 29, the sector’s long-term belief fell from -34 to -42.


Martyn Kendrick, UK head of healthcare banking services at Lloyds Bank, said: “While pharmacists’ confidence has declined somewhat, their short-term outlook has improved for another year, painting a picture of a sector that has begun to bounce back.”

He added that “pharmacists have performed an invaluable service during the lockdown, confirming their place at the heart of our communities.”

The index, a survey of pharmacists, GPs and dentists, has run annually since 2011 and gives a detailed overview of the sector.

Short-term optimism

Around 65 per cent of pharmacists expect to grow their profits in the next year while 62 per cent expect that NHS services to patients will improve.

Lockdown has also boosted the potential for pharmacists, with 61 per cent of them saying they would buy or consider buying another pharmacy.

However, a majority of them feel that financial pressures will increase over the next five years, wavering their confidence.

Online competition

Long-term outlook of pharmacists remains negative as “the sector looks for more clarity on the government’s strategy on disease prevention and managing long-term conditions, including how it will be implemented locally,” the report said.

It noted that 44 per cent of the surveyed pharmacists cited “online rivals as a threat,” indicating a change in consumer behavior during the pandemic.

But, return of normal activity will enable pharmacists to offer more clinical services, which would distinguish them from online operators, it said.

Embracing sustainability

The report said that pharmacists remain committed to improve sustainability of their businesses, with 72 per cent saying it is a vital part of their future plans.

They are working on reduction of waste and paper usage by switching to email and text messages.

Acknowledging challenges faced by pharmacists from online pharmacies, Kendrick said that pharmacists now have the opportunity to expand their range of clinical services and drive new income.

He promised that Lloyds Bank would continue to support pharmacists with guidance and products to meet these targets.

Dr Leyla Hannbeck, chief executive officer at the Association of Independent Multiple Pharmacies, also noted that many see “internet pharmacy as a threat to their business.”

She expected this “trend to weaken as bricks and mortar pharmacies become more focused on delivering clinical services.”

Tony Evans, head of pharmacy at Christie & Co, said: “There have undoubtedly been operational challenges, but pharmacists have learnt a lot about their businesses and the changes they’ve implemented over last 18 months have made them even stronger.”

More For You

NHS app to boost clinical trials

The focus is on encouraging people from underrepresented groups, including minorities from African and Asian heritage, to sign up for clinical trials.

iStock

Government to use NHS app to boost clinical trials

The government’s 10-Year Health Plan is expected to provide a fillip to clinical trials, and it plans to make use of the NHS App to encourage people to sign up as participants.

People will be able to sign up for the NIHR Be Part of Research service (bepartofresearch.uk) on the NHS App for the trials best suited to their interests and needs.

Keep ReadingShow less
US pharma bets big on China to snap up potential blockbuster drugs

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies

US pharma bets big on China to snap up potential blockbuster drugs

US drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters.

Keep ReadingShow less
Alliance Healthcare team raises thousands with charity bike ride to Paris

The Alliance Healthcare team

Alliance Healthcare team raises thousands with charity bike ride to Paris

Eight Alliance Healthcare team members raised over £55,000 for Theodora Children’s Charity by cycling from Surrey to Paris.

From June 13th-15th, the team took on the gruelling 300 mile cross-border Tour D’Alliance 2025 challenge and raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Keep ReadingShow less
Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less